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(−)-Epicatechin protects thoracic aortic
perivascular adipose tissue from whitening in
high-fat fed mice†
Ezequiel J. Hid,a,b Laura Fischerman,a,b Barbara Piotrkowski,a,b María C. Litterio,a,b
Cesar G. Fraga a,b,c and Monica Galleano *a,b
High adipose tissue (AT) accumulation in the body increases the risk for many metabolic and chronic dis-
eases. This work investigated the capacity of the flavonoid (−)-epicatechin to prevent undesirable modifi-
cations of AT in mice fed a high-fat diet. Studies were focused on thoracic aorta perivascular AT (taPVAT),
which is involved in the control of blood vessel tone, among other functions. Male C57BL/6J mice were
fed for 15 weeks a high-fat diet with or without added (−)-epicatechin (20 mg per kg body weight per d).
In high-fat diet fed mice, (−)-epicatechin supplementation: (i) prevented the expansion of taPVAT, (ii) atte-
nuated the whitening of taPVAT (according to the adipocyte morphology, diameter, and uncoupling-
protein 1 (UCP-1) levels) and (iii) blunted the increase in plasma glucose and cholesterol. The observed
taPVAT modifications were not associated with alterations in the aorta wall thickness, aorta tumor necrosis
factor-alpha (TNF-α) and NADPH-oxidase 2 (NOX2) expression, and endothelial nitric oxide synthase
(eNOS) phosphorylation levels. In summary, our results indicate (−)-epicatechin as a relevant bioactive
protecting from the slow and silent development of metabolic and chronic diseases as they are associated
with excessive fat intake.
Introduction
Adipose tissue (AT) dysfunction is associated with a state of
chronic inflammation that is linked to the onset of cardio-
vascular and metabolic diseases, including hypertension, type
2 diabetes, and non-alcoholic fatty liver disease.1 Thus, con-
trolling AT expansion and dysfunction is a strategy to improve
health by reducing the incidence and consequences of those
diseases.
AT has different localization and functional capabilities,
which define two major types of AT, white AT (WAT) and brown
AT (BAT). In terms of distribution in mammals, WAT is mostly
subcutaneous and visceral. The latter includes mesenteric
(mWAT), epididymal (eWAT), retroperitoneal (rWAT), and peri-
renal (pWAT) AT pads. Beyond the well-established interscapu-
lar depots in human infants and rodents, BAT is also present
in adult subjects.2,3 A characteristic that differentiates WAT
and BAT is the density of mitochondria in adipocytes, which is
lower in WAT than in BAT. Also, the use of energy favors lipid
storage in WAT but dissipates as heat in BAT. In addition, a
third type of AT exists surrounding blood vessels, i.e. the peri-
vascular (PVAT). This AT displays features of WAT and BAT.4 In
rodents, PVAT surrounding the abdominal aorta exhibits a
WAT-like phenotype, but the PVAT surrounding the thoracic
aorta (taPVAT) is more similar to BAT in terms of morphology
and functions.
AT pads can interchange their structural, cellular and mole-
cular characteristics in response to both physiological and
pathological conditions.5 This plasticity can result in positive
or negative health effects. Positive examples are the shift from
WAT to BAT (browning) after cold exposure or physical activity.
In contrast, undesirable changes from BAT to WAT (whitening)
occur associated with age and obesity.6
Flavonoids are compounds present in edible fruits and veg-
etables, and increasing evidence supports the benefits of their
consumption in human health.7 Diets rich in flavonoids could
contribute to the browning of WAT.8 Particularly, the flavonoid
(−)-epicatechin has been associated with positive health
effects affecting several disease conditions, including
obesity.9–16 In terms of mechanisms of disease, (−)-epicatechin
supplementation has been shown to mitigate systemic and
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
d0fo01148g
aCátedra de Fisicoquímica, Departamento de Química Analítica y Fisicoquímica,
Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires,
Argentina. E-mail: mgallean@ffyb.uba.ar
bCONICET-Universidad de Buenos Aires, Instituto de Bioquímica y Medicina
Molecular (IBIMOL), Buenos Aires, Argentina
cDepartment of Nutrition, University of California, Davis, CA 95616, USA















































WAT insulin resistance in high-fat fed mice,15 in part due to its
capacity to inhibit WAT inflammation, endoplasmic reticulum
stress and oxidative stress.17,18
In this work, we investigated the capacity of (−)-epicatechin
to prevent pathological modifications of AT developed in mice
fed a high-fat diet. We observed that (−)-epicatechin sup-




Primary antibodies for inducible nitric oxide synthase (iNOS)
(#649), endothelial nitric oxide synthase (eNOS) (#654), inter-
leukin-6 (IL-6) (#1265), tumor necrosis factor (TNF-α) (#52746),
NOX2 catalytic subunit gp91(#5827), and β-actin (#47778), and
secondary antibodies, mouse anti-rabbit IgG-HRP (#2357),
goat anti-mouse IgG-HRP (#2005), and rabbit anti-goat
IgG-HRP (#2768), were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). The primary antibody for phospho-eNOS (Ser
1177) (p-eNOS) (#9570) was from Cell Signaling Technology
(Danvers, MA, USA). The primary antibodies for uncoupling-
protein 1 (UCP-1) (#U6382) and (−)-epicatechin were from
Sigma Aldrich (St Louis, MO, USA).
Animals, diets and experimental design
All procedures were in agreement with standards for the care
of laboratory animals as outlined in the National Institutes of
Health Guide for the Care and Use of Laboratory Animals (NIH
Pub. no. 85-23, Revised 1996) and were approved by the
Institutional Committee for the Care and Use of Laboratory
Animals, School of Pharmacy and Biochemistry, University of
Buenos Aires, Argentina (CUDAP: EXP-UBA: 75405/16).
Male C57BL/6J mice were housed under conditions of con-
trolled temperature (21–25 °C) and humidity, with a 12 h light/
dark cycle. Mice (8 per group) weighing 20 ± 2 g were randomly
divided into the following groups depending on the diet: (i)
control group (C), receiving a control diet (10% of total calories
from lard fat); (ii) control-epicatechin group (CE), receiving the
control diet supplemented with (−)-epicatechin (20 mg per kg
body weight per d); (iii) high-fat group (HF) receiving a high-
fat diet (60% of total calories from lard fat); and (iv) high-fat-
epicatechin group (HFE), receiving the high-fat diet sup-
plemented with (−)-epicatechin (20 mg per kg body weight per
d).18,19 The amount of (−)-epicatechin provided to mice is
equivalent to 200 mg d−1 for a 70 kg human, quantity attain-
able through the optimization of fruit and vegetable intake
and/or pharmacological strategies.10,11 The control and high-
fat diet composition is shown in the ESI.† Pellets were pre-
pared by adding the fat lard or/and (−)-epicatechin once every
two weeks, to adjust the amount of (−)-epicatechin according
to food consumption and animal weight. Dry pellets were
stored at 4 °C. Food intake consumption and body weight were
recorded weekly. After 15 weeks of the respective treatments,
mice were weighed, and euthanized in a CO2 chamber. Blood
was collected from the abdominal aorta into heparinized
tubes and plasma was obtained after centrifugation at 600g for
15 min at 4 °C. Blood plasma samples were frozen at −80 °C.
The clean aorta and the aorta surrounded by taPVAT, eWAT,
mWAT, rWAT, and pWAT were excised immediately and either
processed for histology or flash frozen in liquid N2 for further
analyses.
Biochemical determinations
Glucose, total cholesterol, and triglycerides in plasma were
measured using a Cobas C-501 autoanalyzer (Roche
Diagnostics, Mannheim, Germany).
Western blotting analysis
eWAT and mWAT were homogenized (proportion 1 : 3, w : v) in
lysis buffer (150 mM NaCl, 50 mM Trizma-HCl, 1% (v/v) NP-40,
pH 8.0) in the presence of protease and phosphatase inhibi-
tors, and centrifuged at 600g for 10 min at 4 °C. The super-
natant was collected and considered as total homogenates.
Total homogenates were added to a 2× solution of Laemmli
buffer and heated at 95 °C for 5 min. Sample aliquots contain-
ing 40 μg of protein were separated by reducing 10% (w/v) poly-
acrylamide gel electrophoresis, and electroblotted onto polyvi-
nylidenedifluoride membranes. Colored molecular weight
standards (GE Healthcare, Piscataway, NJ, USA) were run sim-
ultaneously. Membranes were blotted for 2 h in 5% (w/v)
nonfat milk and incubated overnight in the presence of the
corresponding primary antibody (1 : 1000 dilution in PBS).
After a subsequent incubation for 90 min at room temperature
in the presence of the corresponding HRP-conjugated second-
ary antibody (1 : 5000 dilution in PBS), complexes were visual-
ized by chemiluminescence. Films were scanned and the den-
sitometry analysis was performed using Image J (National
Institute of Health, Bethesda, Maryland, USA). Proteins were
normalized to the β-actin content. The protein content of total
homogenates was measured by the Lowry method.20
Histological and immunochemical analysis of AT and aorta
For each animal, a portion of thoracic aorta with surrounding
taPVAT and a portion of eWAT and mWAT were separated, fixed
in phosphate-buffered 10% (v/v) formaldehyde (pH 7.2) and
embedded in paraffin. Three µm sections were cut and stained
with hematoxylin–eosin or Trichrome Masson’s stains.
Histological evaluations were performed using a light micro-
scope Nikon E400 (Nikon Instrument Group, Melville, NY,
USA). To evaluate aorta morphometry, the wall media thick-
ness and lumen diameter were measured. To establish expan-
sion of taPVAT, the area of taPVAT was relativized to the aortic
wall media thickness. Immunohistochemistry of taPVAT was
evaluated with antibodies against UCP-1 (1 : 100 in PBS).
Immunostaining was quantified as the percentage of positive
staining per area from 20 random images viewed at ×400 mag-
nification. Measurements were performed using Image-Pro
Plus version 4.5 for Windows (Media Cybernetics, LP, Silver
Spring, MD, USA).
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Data from food intake, energy intake, body weight, biochemi-
cal parameters, and western blotting analysis were analyzed by
one-way ANOVA followed by Tukey–Kramer’s post-hoc test using
StatView5.0 (SAS Institute, Cary, NC, USA). Histological and
immunohistochemical data were analyzed by the nonpara-
metric Kruskal–Wallis test followed by Dunn’s post-test using
GraphPad Prism 5.01 (GraphPad Software, Inc. San Diego, CA,
USA). All data are presented as mean ± standard error of the
mean (SEM) with significance set at p < 0.05.
Results
Food consumption, energy intake, and body weight during the
treatment period are shown in Fig. 1. Daily food consumption
did not change significantly because of the different treat-
ments. HF and HFE consumed lower amounts of food com-
pared to C and CE (Fig. 1A), with differences among groups
already being observed in the first week under treatment. The
energy intake was calculated considering the food consump-
tion and the caloric value of control and high fat diets, yield-
ing similar caloric intakes among the four groups (Fig. 1B).
Body weight increases were similar for the four experimental
groups during the first 4 weeks, and were higher for the
groups receiving the high-fat diet during the remaining treat-
ment period (Fig. 1C). The final body weight in HF and HFE
was significantly higher than that observed in C and CE
(Fig. 1D). Body weight gain was independent of the presence
of (−)-epicatechin in the diet.
Glycemia and blood lipid parameters were determined as
indexes of systemic cardiometabolic responses to the diets
(Table 1). Glycemia was significantly higher in HF (p < 0.05) as
compared to C, CE and HFE. Total plasma cholesterol was sig-
nificantly higher in HF as compared to C and CE; no differ-
ence was found for total cholesterol between HFE and, both C
and CE. Triglyceride levels showed no differences among the
groups.
The relative mass of eWAT, mWAT, rWAT, and pWAT depots
was significantly higher in HF and HFE compared to C and CE
Fig. 1 Food and energy intake and body weight. Daily food intake (A), daily energy intake (B), body weight (C), and final body weight (D) from CE, C,
HF and HFE. Results are expressed as means ± SEM (n = 8). *p < 0.05 vs. C and CE. #p < 0.05 vs. all other groups.
Table 1 Effect of (−)-epicatechin on metabolic parameters in high-fat
fed mice
Variablea CE C HF HFE
Glucose (mg dl−1) 304 ± 33 275 ± 40 399 ± 29# 307 ± 12
Total cholesterol (mg dl−1) 100 ± 11 99 ± 8 142 ± 13* 119 ± 8
Triglycerides (mg dl−1) 35 ± 3 47 ± 8 35 ± 6 51 ± 4
a Variables were measured in plasma under non-fasting conditions.
Results are expressed as means ± SEM (n = 8). #p < 0.05 vs. all other
groups.*p < 0.05 vs. C.
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(Fig. 2). This resulted in an intra-abdominal adiposity (sum of
the four fat pads relative to the body weight) of 84 ± 6 and 82 ±
5 mg g−1 for HF and HFE, respectively, that has no significant
difference between them, but higher than the values reported
for C and CE (52 ± 5 and 63 ± 5 mg g−1, p < 0.05).
Fig. 3 and 4 show the effects of the high-fat diet and of
(−)-epicatechin supplementation on several characteristics of
WAT pads. Representative images of hematoxylin–eosin
stained eWAT and mWAt are shown in Fig. 3A and 4A, respect-
ively. For eWAT, the analysis of adipocyte size distribution
according to its diameter (Fig. 3B) showed that: (i) the percen-
tage of medium (51–75 µm) and large adipocytes (76–100 µm)
was similar for the four experimental groups; (ii) the percen-
tage of small adipocytes (25–50 µm) was lower in HF compared
with C, CE and HFE; and (iii) the percentage of very large adi-
pocytes (>100 µm) was higher in HF and HFE than for C and
CE. The expression of the pro-inflammatory molecules, IL-6
and iNOS, was evaluated by western blotting. In eWAT, IL-6
expression was similar in C, CE and HF, and significantly
lower (≈46% respect to HF, p < 0.05) in HFE (Fig. 3C).
Meanwhile, no significant differences were found in iNOS
expression among the four experimental groups (Fig. 3D).
Similar results were observed in mWAT. The adipocyte size dis-
tribution results showed that: (i) the percentage of medium
(51–75 µm) and large adipocytes (76–100 µm) was similar in
the four experimental groups; (ii) the percentage of small adi-
pocytes (25–50 µm) was lower in HF compared with C, CE and
HFE; and (iii) the percentage of very large adipocytes
(>100 µm) was higher in HF and HFE than in C and CE
(Fig. 4B). IL-6 expression was similar in C, CE and HF, and sig-
nificantly lower (≈40% compared to HF, p < 0.05) in HFE
(Fig. 4C). Meanwhile, no significant differences were found in
iNOS expression among the four experimental groups
(Fig. 4D).
Morphometric characteristics of taPVAT are shown in
Fig. 5A. The expansion of taPVAT was estimated through the
ratio of taPVAT area/media thickness of the thoracic aorta. This
ratio was significantly higher in HF (75%, p < 0.05) compared
to C, CE, and HFE (Fig. 5B). Histological characterization of
adipocytes showed clear differences between taPVAT character-
istics in C and CE with respect to HF (Fig. 6A and B). Most of
the taPVAT in C and CE showed a BAT-like appearance (round
nuclei, and small and multilocular lipid droplets), and dis-
persed WAT-like adipocytes (flattened non-central nuclei, and
Fig. 2 Relative WAT pad weight. Epididymal (eWAT) (A), mesenteric (mWAT) (B), retroperitoneal (rWAT) (C), and perirenal (pWAT) (D) from CE, C, HF
and HFE. Results are expressed as means ± SEM (n = 8). *p < 0.05 vs. C and CE.
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big lipid droplets). In HF there was a clear inversion in the pro-
portion of adipocyte phenotypes from BAT to WAT; meanwhile
HFE showed an intermediate phenotype, closer to C and CE.
Quantification of the adipocyte size showed that the diameter
was significantly lower in HFE compared to HF (29%, p < 0.05)
(Fig. 6B). Additional confirmation of the BAT characteristics of
the taPVAT was obtained by UCP-1 staining. The presence of
UCP-1 showed a similar pattern/distribution to that observed
for the adipocyte size (Fig. 6A and C). Quantification of UCP-1
staining shows that while about 68% of staining was observed
in C and CE, only 16% was observed in HF (p < 0.05). In HFE,
the staining was 48%, being significantly higher than that in
HF (p < 0.05) and lower than that in C and CE (p < 0.05)
(Fig. 6D).
The physiological actions of taPVAT result in vascular remo-
deling and function of the aorta. The four experimental groups
showed a similar aorta wall thickness relative to the lumen dia-
meter (Fig. 7A), suggesting the absence of vascular smooth
muscle cell proliferation. In addition, no significant changes
were observed in the expression of an inflammatory marker in
the aorta, such as TNF-α (Fig. 6B) as well as in determinants of
nitric oxide bioavailability: (i) the expression of gp91, the cata-
lytic subunit of NOX2 (Fig. 6B and C); and (ii) the phosphoryl-
ation of eNOS (p-eNOS/eNOS).
Fig. 3 Cell size distribution and expression of pro-inflammatory molecules in eWAT. eWAT representative images after hematoxylin–eosin staining
(A), quantification of eWAT adipocyte size distribution (B), and IL-6 (C) and iNOS (D) expression in eWAT from CE, C, HF and HFE obtained by western
blotting. β-Actin was used as the loading control. Results are expressed as means ± SEM. For statistics details see the statistical analysis section. *p <
0.05 vs. C and CE. #p < 0.05 vs. all other groups.
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High AT accumulation in the body increases the risk for
many metabolic and chronic diseases. The potential man-
agement through bioactives of undesirable changes that
accompany the consumption of high calorie diets and AT
expansion can have a major impact on health. This work
investigated the capacity of (−)-epicatechin to prevent
adverse modifications of the AT in mice fed a high-fat diet. A
major finding was that (−)-epicatechin supplementation
attenuated the whitening of taPVAT, i.e. enlarged adipocytes
and lower UCP-1 levels, induced by the high-fat diet. In par-
allel, the increases in plasma glucose and cholesterol associ-
ated with high-fat diet consumption were blunted by
(−)-epicatechin.
Experiments were carried out in a C57BL/6J sub-strain in
which the high-fat diet did not lead to overt obesity. Thus,
mice fed the high-fat diet showed a body weight 13% higher
than mice fed the control diet, which is a moderate response
compared to other data reported for the same strain, food and
time of treatments, i.e. 35–45%.15,17,18,21 This modest increase
in weight gain allowed us to analyze the effects of (−)-epicate-
chin in an early stage of high-fat diet-induced dysmetabolism.
The increase in weight in HF and HFE despite the similar
caloric intake compared to C and CE could be explained by the
fact that fat is energetically more efficient than carbohydrates
and proteins to promote greater positive energy balance and
fat accumulation.22,23
In mice consuming the high-fat diet, both body weight and
intra-abdominal adiposity were not affected by (−)-epicatechin
Fig. 4 Cell size distribution and expression of pro-inflammatory molecules in mWAT. mWAT representative images of hematoxylin–eosin staining
(A), quantification of mWAT adipocyte size distribution (B), and IL-6 (C) and iNOS (D) expression in mWAT from CE, C, HF and HFE obtained by
western blotting. β-Actin was used as the loading control. Results are expressed as means ± SEM. For statistics details see the statistical analysis
section. *p < 0.05 vs. C and CE. °p < 0.05 vs. HF.
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supplementation, while increases in glycemia and plasma
cholesterol were partially or totally prevented. Mitigation of
high-fat induced alterations in plasma glucose and dyslipide-
mia was previously reported to be associated with (−)-epicate-
chin intake.15,17,24,25 These results support the protective
action of (−)-epicatechin in diet-induced metabolic disorders,
even in the absence of extreme changes in body weight and/or
fat accumulation.
Increasing evidence suggests that the pathogenesis of
obesity is to a large extent related to both a pathological expan-
sion of WAT pads and systemic inflammation.26 AT expansion
can occur through hyperplasia (increased number of cells)
and/or hypertrophy (increased cell size).27 WAT hypertrophy is
characterized by the presence of large and very large adipo-
cytes28 with a pro-inflammatory profile.29–31 In the present
work, the adipocyte size distribution was similar for high-fat
fed and control fed mice, suggesting that the predominant
expansion mechanism was hyperplasia. In agreement with
this, both eWAT and mWAT pads in high-fat fed mice did not
show a pro-inflammatory condition as determined by adipo-
cyte levels of IL-6 and iNOS. Interestingly, the minimal
changes manifested in the percentage of small and large/very
large adipocytes in HF were not present when (−)-epicatechin
was supplemented in the diet. These results are in agreement
with previous reports showing systemic and local anti-inflam-
matory effects of (−)-epicatechin32,33 and specifically in WAT
pads modified by a high-fat diet.17,24 Similar effects of (−)-epi-
catechin were observed even in the offspring of female mice
fed a high-fat diet.34
PVAT secretes vasocontractile and vasorelaxant factors,
involved in the control of blood vessel tone,35 as well as a set
of molecules with anti-atherogenic and anti-inflammatory
functions.36–41 In the case of taPVAT, its BAT-like phenotype
is crucial for the maintenance of the normal structure and
function of the thoracic aorta segment; meanwhile its
whitening would be deleterious. This study shows that
taPVAT was drastically transformed by the consumption of a
high-fat diet, acquiring the features of WAT, while the WAT
pads showed a mild expansion, due to adipocyte hyperpla-
sia, without a substantial pro-inflammatory condition.
Therefore, the taPVAT whitening emerges as an early hall-
mark of alterations induced by a high-fat diet.
(−)-Epicatechin supplementation was associated with the
absence of taPVAT expansion and the attenuation of its
transformation into WAT-type adipocytes, as evidenced by
adipocyte morphology and UCP-1 expression. Accordingly,
(−)-epicatechin has shown effects as a WAT browning agent
in experimental models of diet-induced obesity and in adi-
pocytes in culture. In rats fed a high-fat diet, the adminis-
tration of (−)-epicatechin promoted an increase in the
abdominal WAT expression of UCP-1 and deionidase-2, both
normally expressed in BAT adipocytes.42 More recently, in a
similar mouse model, (−)-epicatechin showed a WAT brown-
ing effect evidenced by the increased expression of key BAT-
proteins, including UCP-1.43 The modulatory effects of
(−)-epicatechin reversing/attenuating the taPVAT whitening
could be explained by its capacity to mitigate the down-regu-
lation of BAT of the peroxisome proliferator-activated recep-
Fig. 5 taPVAT expansion. Transversal sections of the thoracic aorta and taPVAT stained with hematoxylin–eosin (4×) (A), and ratio area of taPVAT/
media layer thickness of the aorta (B) from CE, C, HF and HFE. Results are expressed as means ± SEM (n = 4). #p < 0.05 vs. all other groups.
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tor γ (PPARγ) and other proteins involved in mitochondrial
biogenesis (PPARγ coactivador-1α-PGC-1α-, and PR domain-
containing 16-PRDM16-) and mitochondrial function
(UCP-1). Those mechanisms were also shown to occur in
3T3-L1 adipocytes subjected to inflammatory conditions44 or
exposed to palmitate.45
Finally, it is relevant to consider that the observed taPVAT
modifications were not associated with alterations in aorta
remodeling, i.e. changes in the aorta wall thickness, inflam-
mation, i.e. TNF-α expression, and determinants of superoxide
anion and nitric oxide availability. The latter is suggested by
the absence of changes in both aorta NOX2 catalytic subunit
gp91, and the phosphorylation of eNOS. These results agree
with the concept that some aspects of the vascular pathology
induced by high-fat diets are due to the development of dys-
functional PVAT.41
It is important to note that for all parameters studied
(−)-epicatechin had non-significant effects in mice fed the
control diet. This absence of effects suggests that (−)-epicate-
chin (as well as other related flavonoids) generally mitigates
Fig. 6 Cell size and UCP-1 immnunostaining in taPVAT. Representative images (A), and adipocyte diameter (B) of taPVAT stained with Masson’s
Trichrome (40×), representative images (C), and quantification (D) of UCP-1 staining in taPVAT from CE, C, HF and HFE evaluated with immunohisto-
chemistry. Results are expressed as means ± SEM (n = 4). *p < 0.05 vs. C and CE. #p < 0.05 vs. all other groups.
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deviations related to pathological conditions, such those trig-
gered by the high-fat diet consumption.16
In summary, (−)-epicatechin provided protecting effects in
mice fed a high-fat diet in terms of fat metabolism. One of the
most significant effects was the prevention of taPVAT acqui-
sition of WAT features affording a crucial strategy to maintain
a healthy vasculature. Other positive actions of (−)-epicatechin
were observed reverting metabolic changes triggered by exces-
sive fat consumption. These observations make (−)-epicatechin
a valuable bioactive protecting from slow and silent develop-
ment of metabolic diseases.
Abbreviations
AT Adipose tissue
BAT Brown adipose tissue
eNOS Endothelial nitric oxide synthase
eWAT Epididymal white adipose tissue
mWAT Mesenteric white adipose tissue
NOX2 NADPH-oxidase 2
iNOS Inducible nitric oxide synthase
pWAT Perirenal white adipose tissue
PVAT Perivascular adipose tissue
rWAT Retroperitoneal white adipose tissue
taPVAT Thoracic aorta perivascular adipose tissue
TNF-α Tumor necrosis factor
UCP-1 Uncoupling-protein 1
WAT White adipose tissue
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Fig. 7 Aorta morphometry and expression of TNF-α, and gp91, and eNOS phosphorylation levels in the aorta. Wall thickness/lumen diameter (A),
expression of TNF-α(B), and gp91 (C), and peNOS/eNOS ratio (D) in the aorta from CE, C, HF and HFE. β-Actin was used as the loading control.
Results are expressed as means ± SEM (n = 5).
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